Xencor (NASDAQ:XNCR) SVP Celia Eckert Sells 3,244 Shares

Xencor, Inc. (NASDAQ:XNCR) SVP Celia Eckert sold 3,244 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $11.25, for a total transaction of $36,495.00. Following the completion of the transaction, the senior vice president owned 78,685 shares of the company’s stock, valued at $885,206.25. This trade represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Celia Eckert also recently made the following trade(s):

• On Friday, March 6th, Celia Eckert sold 1,767 shares of Xencor stock. The stock was sold at an average price of $11.02, for a total transaction of $19,472.34.
• On Tuesday, March 3rd, Celia Eckert sold 1,492 shares of Xencor stock. The shares were sold at an average price of $11.90, for a total transaction of $17,754.80.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $11.87 on Tuesday. Xencor, Inc. has a 1 year low of $6.92 and a 1 year high of $18.69. The stock has a market capitalization of $870.55 million, a P/E ratio of -9.57 and a beta of 0.95. The company’s 50-day moving average is $12.73 and its 200 day moving average is $13.03. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.25 and a quick ratio of 6.25.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.55. The business had revenue of $28.24 million during the quarter, compared to analyst estimates of $29.97 million. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. Xencor’s quarterly revenue was down 46.6% compared to the same quarter last year. During the same period last year, the business posted ($0.62) earnings per share. On average, sell-side analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Monday, December 29th. Barclays upped their price target on Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Truist Financial started coverage on Xencor in a report on Monday, November 24th. They issued a “buy” rating and a $29.00 price objective for the company. Finally, Wall Street Zen lowered Xencor from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Hedge Funds Weigh In On Xencor

Large investors have recently made changes to their positions in the business. Hantz Financial Services Inc. lifted its holdings in shares of Xencor by 209.1% during the third quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 2,156 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 1,449 shares during the last quarter. Farther Finance Advisors LLC purchased a new stake in shares of Xencor in the 3rd quarter worth approximately $44,000. Tower Research Capital LLC TRC increased its position in Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 3,018 shares in the last quarter. Finally, Federated Hermes Inc. increased its position in Xencor by 114.3% during the 3rd quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 2,105 shares in the last quarter.

Key Xencor News

Here are the key news stories impacting Xencor this week:

• Negative Sentiment: Xencor and Genentech have agreed to end their protein-therapeutics collaboration. This removes a strategic partner that could have provided development resources, milestone and/or royalty payments tied to the collaboration and could delay or change the path-to-market for affected programs; however, termination may return rights to Xencor and let the company seek new partners or advance programs independently. Xencor, Genentech to End Protein Therapeutics Collaboration
• Negative Sentiment: Multiple insider sales by senior Xencor executives were disclosed this week: CEO Bassil Dahiyat sold 14,870 shares on March 5 and 6,606 shares on March 6 (total 21,476 shares), SVP Celia Eckert sold 5,011 shares across March 5–6, and VP John Desjarlais sold 6,620 shares across March 5–6. Aggregate proceeds reported are in the low six-figure range per trade. These clustered sales by top executives can be read negatively by the market (profit-taking or reduced insider conviction), unless part of pre-planned 10b5‑1 arrangements (no such plan was disclosed in these notices). Relevant SEC filings: CEO Form 4(s) SVP Form 4(s) VP Form 4(s)

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.